Treatment Overview

For many people, a diagnosis of atherosclerosis comes as a surprise, often discovered during routine testing or after a warning sign like chest pain. This condition, characterized by the hardening and narrowing of the arteries, can create significant anxiety about future health events like heart attacks or strokes. It often forces a sudden awareness of how lifestyle and biology interact. While the thought of blocked arteries is frightening, the condition is highly manageable with modern medicine.

Treatment is critical to slow or stop the buildup of plaque, improve blood flow, and prevent the formation of blood clots that cause life-threatening emergencies. The ultimate goal is to protect the heart, brain, and limbs from damage. Because atherosclerosis affects everyone differently, some have high cholesterol while others struggle with high blood pressure or inflammation, treatment plans are tailored to individual risk factors (American Heart Association, 2024).

Overview of treatment options for Atherosclerosis

The management of atherosclerosis is aggressive and preventative. The primary objective is to stabilize existing plaque to prevent it from rupturing and to stop new plaque from forming. While lifestyle changes such as diet modification and smoking cessation are foundational, medication is almost always required to achieve the necessary biological control.

Pharmacological treatment targets the specific drivers of arterial damage: high cholesterol, high blood pressure, and the blood’s tendency to clot. For severe blockages that restrict blood flow significantly, procedures like angioplasty or bypass surgery may be necessary. However, for most patients, a consistent regimen of medication is the primary defense against disease progression.

Medications used for Atherosclerosis

The most common first-line medications are statins. Drugs like atorvastatin and rosuvastatin are prescribed to lower low-density lipoprotein (LDL), often called “bad” cholesterol. Clinical experience suggests that statins not only lower cholesterol numbers but also help stabilize the plaque lining the arteries, making it less likely to rupture.

For patients who cannot tolerate statins or do not reach their goals with statins alone, doctors may prescribe ezetimibe, which blocks cholesterol absorption from food. Newer injectable medications known as PCSK9 inhibitors are also available for aggressive cholesterol lowering.

Anti-platelet medications are another critical category. Aspirin or clopidogrel are frequently prescribed to thin the blood slightly. These are used to prevent clots from forming on top of the plaque.

Additionally, managing blood pressure is essential. ACE inhibitors (like lisinopril) and beta-blockers (like metoprolol) are commonly used to reduce the strain on the arteries and slow the heart rate. Patients typically do not “feel” these medications working, but they are effective at reducing the risk of cardiovascular events over time (National Heart, Lung, and Blood Institute, 2022).

How these medications work

Statins work by blocking a specific enzyme in the liver that is responsible for producing cholesterol. By reducing the amount of cholesterol circulating in the blood, the body is less likely to deposit fat into the artery walls. Furthermore, statins have anti-inflammatory properties that help “harden” existing soft plaque, making it more stable.

Anti-platelet drugs target the blood cells responsible for clotting. Platelets are sticky cells that rush to the site of an injury. In atherosclerosis, a ruptured plaque can look like an injury to the body. These medications make platelets “slippery,” preventing them from clumping together and blocking the artery. ACE inhibitors work by relaxing blood vessels, which lowers blood pressure and reduces the force of blood pumping against the arterial walls.

Side effects and safety considerations

Statins are usually safe but can cause mild muscle pain/weakness; persistent pain requires a doctor’s visit. Anti-platelets increase bleeding risk, causing easier bruising or slower wound clotting.

ACE inhibitors may cause a dry cough. Certain cholesterol drugs necessitate liver function monitoring. Most of these drugs, especially statins, are unsafe during pregnancy. Seek immediate medical attention for sudden chest pain, difficulty breathing, or stroke signs (e.g., facial drooping, slurred speech) (Mayo Clinic, 2023).

Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care.

References

  1. American Heart Association. https://www.heart.org
  2. Mayo Clinic. https://www.mayoclinic.org
  3. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov
  4. MedlinePlus. https://medlineplus.gov

Medications for Atherosclerosis

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Atherosclerosis.

Found 8 Approved Drugs for Atherosclerosis

Plavix

Generic Name
Clopidogrel

Plavix

Generic Name
Clopidogrel
Form: Tablet
Method of administration: Oral
FDA approval date: November 17, 1997
Classification: P2Y12 Platelet Inhibitor
Clopidogrel tablets are a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome - For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], clopidogrel tablets have been shown to reduce the rate of myocardial infarction (MI) and stroke.

Rosuvastatin

Brand Names
Crestor, Rosuvastain, Ezallor

Rosuvastatin

Brand Names
Crestor, Rosuvastain, Ezallor
Form: Tablet, Capsule
Method of administration: Oral
FDA approval date: July 19, 2016
Classification: HMG-CoA Reductase Inhibitor
EZALLOR SPRINKLE is indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and at least one additional CV risk factor., As an adjunct to diet to: o Reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia. o Reduce LDL-C and slow the progression of atherosclerosis in adults. o Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH)., As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH)., As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. EZALLOR SPRINKLE is an HMG Co-A reductase inhibitor (statin) indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of CV disease based on age, high- sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and at least one additional CV risk factor. As an adjunct to diet to: reduce LDL-C in adults with primary hyperlipidemia. reduce LDL-C and slow the progression of atherosclerosis in adults. reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia.

Altoprev

Generic Name
Lovastatin

Altoprev

Generic Name
Lovastatin
Form: Tablet
Method of administration: Oral
FDA approval date: December 17, 2001
Classification: HMG-CoA Reductase Inhibitor
Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10 to 17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >189 mg/dL or 2. LDL-C remains >160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL.

Xarelto

Generic Name
Rivaroxaban

Xarelto

Generic Name
Rivaroxaban
Form: Tablet, Kit, Granule, For
Method of administration: Oral
FDA approval date: July 01, 2011
Classification: Factor Xa Inhibitor
XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation.

Pravastatin

Generic Name
Pravastatin

Pravastatin

Generic Name
Pravastatin
Form: Tablet
Method of administration: Oral
FDA approval date: April 25, 2006
Classification: HMG-CoA Reductase Inhibitor
Prevention of Cardiovascular Disease In hypercholesterolemic patients without clinically evident coronary heart disease (CHD), pravastatin sodium tablets are indicated to: reduce the risk of myocardial infarction (MI)., reduce the risk of undergoing myocardial revascularization procedures., reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. In patients with clinically evident CHD, pravastatin sodium tablets are indicated to:, reduce the risk of total mortality by reducing coronary death., reduce the risk of MI., reduce the risk of undergoing myocardial revascularization procedures., reduce the risk of stroke and stroke/transient ischemic attack (TIA)., slow the progression of coronary atherosclerosis. Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD. Limitations of Use Pravastatin sodium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V). Hyperlipidemia Pravastatin sodium tablets are indicated: as an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and triglyceride (TG) levels and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia ( Fredrickson Types IIa and IIb). 1, as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV)., for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet., as an adjunct to diet and lifestyle modification for treatment of heterozygous familial hypercholesterolemia (HeFH) in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present:, LDL-C remains ≥190 mg/dL or, LDL-C remains ≥160 mg/dL and:, there is a positive family history of premature cardiovascular disease (CVD) or, two or more other CVD risk factors are present in the patient.
Showing 1-5 of 8
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances